CL2023001556A1 - Proteínas de unión a il-7 y su uso en tratamientos médicos - Google Patents
Proteínas de unión a il-7 y su uso en tratamientos médicosInfo
- Publication number
- CL2023001556A1 CL2023001556A1 CL2023001556A CL2023001556A CL2023001556A1 CL 2023001556 A1 CL2023001556 A1 CL 2023001556A1 CL 2023001556 A CL2023001556 A CL 2023001556A CL 2023001556 A CL2023001556 A CL 2023001556A CL 2023001556 A1 CL2023001556 A1 CL 2023001556A1
- Authority
- CL
- Chile
- Prior art keywords
- binding proteins
- medical treatments
- treatments
- medical
- interleukin
- Prior art date
Links
- 108091008324 binding proteins Proteins 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 101100508567 Mus musculus Il7 gene Proteins 0.000 title 1
- 102000000704 Interleukin-7 Human genes 0.000 abstract 2
- 108010002586 Interleukin-7 Proteins 0.000 abstract 2
- 229940100994 interleukin-7 Drugs 0.000 abstract 2
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En el presente documento se proporcionan proteínas de unión a interleucina 7 (IL-7), composiciones farmacéuticas y su uso en el tratamiento o prevención de una enfermedad o afección.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063120564P | 2020-12-02 | 2020-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001556A1 true CL2023001556A1 (es) | 2023-11-10 |
Family
ID=78844686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001556A CL2023001556A1 (es) | 2020-12-02 | 2023-05-31 | Proteínas de unión a il-7 y su uso en tratamientos médicos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11802150B2 (es) |
| EP (1) | EP4255928A1 (es) |
| JP (1) | JP2023551935A (es) |
| KR (1) | KR20230098288A (es) |
| CN (1) | CN116547002A (es) |
| AR (1) | AR124286A1 (es) |
| AU (1) | AU2021391493A1 (es) |
| CA (1) | CA3199648A1 (es) |
| CL (1) | CL2023001556A1 (es) |
| CO (1) | CO2023007851A2 (es) |
| IL (1) | IL303134A (es) |
| MX (1) | MX2023006294A (es) |
| TW (1) | TWI821804B (es) |
| WO (1) | WO2022117526A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR129445A1 (es) * | 2022-05-27 | 2024-08-28 | Glaxosmithkline Ip Dev Ltd | USO DE PROTEÍNAS DE UNIÓN A TNF-a Y PROTEÍNAS DE UNIÓN A IL-7 EN EL TRATAMIENTO MÉDICO |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7504256B1 (en) | 1999-10-19 | 2009-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| CA2499816C (en) | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| JP2008512353A (ja) | 2004-07-21 | 2008-04-24 | グライコフィ， インコーポレイテッド | 主にＧｌｃＮＡｃ２Ｍａｎ３ＧｌｃＮＡｃ２グリコフォームを含むイムノグロブリン |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| PT2506871T (pt) | 2009-11-30 | 2016-11-07 | Janssen Biotech Inc | Mutantes de fc de anticorpos com funções efetoras inutilizadas |
-
2021
- 2021-11-30 AR ARP210103301A patent/AR124286A1/es unknown
- 2021-11-30 CA CA3199648A patent/CA3199648A1/en active Pending
- 2021-11-30 EP EP21823820.2A patent/EP4255928A1/en active Pending
- 2021-11-30 MX MX2023006294A patent/MX2023006294A/es unknown
- 2021-11-30 IL IL303134A patent/IL303134A/en unknown
- 2021-11-30 US US17/538,431 patent/US11802150B2/en active Active
- 2021-11-30 CN CN202180081029.5A patent/CN116547002A/zh active Pending
- 2021-11-30 TW TW110144544A patent/TWI821804B/zh active
- 2021-11-30 KR KR1020237018159A patent/KR20230098288A/ko active Search and Examination
- 2021-11-30 JP JP2023533733A patent/JP2023551935A/ja active Pending
- 2021-11-30 AU AU2021391493A patent/AU2021391493A1/en active Pending
- 2021-11-30 WO PCT/EP2021/083465 patent/WO2022117526A1/en active Application Filing
-
2023
- 2023-05-31 CL CL2023001556A patent/CL2023001556A1/es unknown
- 2023-06-15 CO CONC2023/0007851A patent/CO2023007851A2/es unknown
- 2023-09-05 US US18/460,944 patent/US12122828B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023007851A2 (es) | 2023-06-30 |
| AU2021391493A1 (en) | 2023-06-08 |
| AR124286A1 (es) | 2023-03-15 |
| JP2023551935A (ja) | 2023-12-13 |
| US11802150B2 (en) | 2023-10-31 |
| US20240025988A1 (en) | 2024-01-25 |
| KR20230098288A (ko) | 2023-07-03 |
| MX2023006294A (es) | 2023-06-13 |
| AU2021391493A9 (en) | 2024-05-23 |
| WO2022117526A1 (en) | 2022-06-09 |
| IL303134A (en) | 2023-07-01 |
| TW202237183A (zh) | 2022-10-01 |
| CN116547002A (zh) | 2023-08-04 |
| US12122828B2 (en) | 2024-10-22 |
| CA3199648A1 (en) | 2022-06-09 |
| US20220169717A1 (en) | 2022-06-02 |
| TWI821804B (zh) | 2023-11-11 |
| EP4255928A1 (en) | 2023-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020009625A2 (es) | Inhibidor de fap | |
| CY1118519T1 (el) | Συνθεση τετρακυκλινων και αναλογων αυτων | |
| CY1118006T1 (el) | Χρηση γαλακτοβακιλλων για την αγωγη ιικων λοιμωξεων | |
| CY1126152T1 (el) | Ενωσεις-αναστολεις της rip1 και μεθοδοι παρασκευης και χρησης αυτων | |
| CY1107467T1 (el) | Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων | |
| CY1125104T1 (el) | Συνθεσεις φλαγελλινης entrecoccus για χρηση στη θεραπεια | |
| MX2020008208A (es) | Agentes de unión a fibroblastos y uso de estos. | |
| CA3155883A1 (en) | BUCCO-DENTAL CARE COMPOSITIONS BASED ON BETA ACID OF HOPS AND AMINO ACID | |
| WO2022167816A3 (en) | Antibodies | |
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| ECSP066805A (es) | Compuestos silinano como inhibidores de cisteína proteasa | |
| AR122380A1 (es) | Uso de inhibidores de sglt-2 para la prevención y/o tratamiento de enfermedades cardíacas en felinos | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
| AU2018326364A1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease | |
| MX2022005547A (es) | Derivados terapeuticos de interleucina-22. | |
| CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
| CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| CO2023007851A2 (es) | Proteínas de unión a il-7 y su uso en tratamientos médicos | |
| CR20220374A (es) | Métodos de tratamiento de la esplenomegalia | |
| MX2023009971A (es) | Composicion farmaceutica que contiene anticuerpo anti-tslp. | |
| ECSP045397A (es) | 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS | |
| WO2021004958A3 (en) | Compositions comprising bacterial strains | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| BR112023000229A2 (pt) | Composto, composição farmacêutica, e, peptídeo |